ESI Group: A More Inclusive and Safer Industry for Women and Everyone Thanks to Simulation
8.3.2023 23:35:00 EET | Business Wire | Press release
Regulatory News:
ESI Group (Paris:ESI) (ISIN Code: FR0004110310, Symbol: ESI) is a global partner in simulation and virtual prototyping software for various industries. The company is committed to promoting gender equality through various actions, including the recruitment of women and their professional development within the industry. In addition, the Group is advocating for a swift change in legislation to allow the use of virtual prototyping in certification tests in the automotive industry, with the ultimate goal of ensuring the safety of all users, irrespective of their gender or body shape.
According to the World Economic Forum, women are 47% more likely than men to be seriously injured in a car accident. The study of the Insurance Institute of Highway Safety (IIHS) published in 2021 underlines that women have a mortality rate 20 to 28% higher than men during a road accident, a situation explained in part because of the poor consideration of female morphology in crash tests.
Florence Barré, Women@ESI General Delegate and Chief of Staff to Cristel de Rouvray, CEO of ESI Group: " The role of digitization in ensuring highway safety cannot be overstated. By incorporating diverse morphologies in simulations, virtual prototyping can better protect the entire population. Although the automotive industry has widely adopted virtual prototyping, the use of virtual human models that account for a wide range of morphologies remains optional. Therefore, legislators must take an active role in encouraging the systematic adoption of these practices to ensure optimal safety for all users, regardless of their gender or body shape."
Crash tests that no longer correspond to the reality of society
The current system that we have inherited today has remained relatively unchanged for the past 50 years. Mandatory physical tests in the automotive industry no longer reflect the reality of modern society. Shockingly, only one out of the five dummy models used in crash tests until recently was designed to represent female physiology. This particular model, created in the late 1980s, was based on just 5% of the female population and was mostly used in the front and rear passenger positions, with very little consideration for the driver's seat in regulatory test scenarios.
Towards a major breakthrough?
In a significant milestone for both technological advancement and industry awareness, a team of Swedish engineers announced the creation of the world's first female crash test dummy late last year. This achievement highlights the increasing importance of gender inclusion and equality, which are rapidly gaining traction worldwide. However, the question remains: how can we ensure that this breakthrough is accessible and available to all?
The use of digital human models
ESI Group firmly believes that regulatory evolution is necessary to encourage the adoption of agile and inclusive methods, rather than relying solely on physical tests and prototypes as reference tools for passive safety certifications. Moving towards a more virtual and diverse approach enables the representation of current driving practices, including various morphotypes and passenger positions.
Virtual prototyping allows for flexible parameter modifications and facilitates testing on all morphotypes, enabling even more comprehensive results. Additionally, simulation can incorporate morphological diversity in a faster and less expensive manner. Many of ESI Group's industrial partners are already utilizing virtual prototyping to address this challenge. In fact, ESI Group was the first to perform a virtual crash test on the Volkswagen Polo back in 1985, allowing major automotive OEMs to conduct virtual testing of their prototypes instead of costly and time-consuming physical tests.
About ESI Group
Founded in 1973, ESI Group envisions a world where Industry commits to bold outcomes, addressing high stakes concerns - environmental impact, safety & comfort for consumers and workers, adaptable and sustainable business models. ESI provides reliable and customized solutions anchored on predictive physics modeling and virtual prototyping expertise to allow industries to make the right decisions at the right time, while managing their complexity. Acting principally in automotive & land transportation, aerospace, defense & naval and heavy industry, ESI is present in more than 20 countries, employs 1000 people around the world and reported 2022 sales of €130 million. ESI is headquartered in France and is listed on compartment B of Euronext Paris.
For further information, go to www.esi-group.com.
Follow ESI LinkedIn | Facebook | Twitter | YouTube
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005777/en/
Contact information
ESI Group
Florence Barré
press@esi-group.com
+33 1 49 78 28 28
Aline Besselièvre
aline.besselievre@gmail.com
+33 6 61 85 10 05
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million milestone payment to Biocytogen. According to IDEAYA, the Phase 1 study is designed to characterize IDE034’s safety profile, tolerability, and PK as a monotherapy, and IDEAYA also intends to evaluate combination regimens with DNA damage response (DDR) -targeting agents such as its oral PARG inhibitor IDE161 as the program advances. IDE034 is a potential first-in-class bispecific B7H3/PTK7 TOP1 ADC, independently developed by Biocytogen and lice
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 14:00:00 EET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 13:00:00 EET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP) Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 Constraints Not Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. C
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 10:15:00 EET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 09:18:00 EET | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers compared to currently available technologies. This in turn is boosting expectations
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
